Table 2.
AEs occurring during CPX-351 therapy, regardless of causality
| All grades | Grade ≥3 | |
|---|---|---|
| Sepsis | — | 101 (98) |
| Febrile neutropenia | 94 (91) | 94 (91) |
| Pneumonia | 37 (36) | 30 (30) |
| Bacteremia | — | 25 (24) |
| Invasive pulmonary aspergillosis | — | 10 (10) |
| Bleeding | 12 (12) | 6 (6) |
| Epistaxis | 4 (4) | 0 |
| Oral hemorrhage | 2 (2) | 1 (1) |
| Gastrointestinal hemorrhage | 1 (1) | 1 (1) |
| Intra-alveolar hemorrhage | 1 (1) | 1 (1) |
| Intracranial hemorrhage | 2 (2) | 0 |
| Hematuria | 1 (1) | 1 (1) |
| Ocular hemorrhage | 1 (1) | 0 |
| Hypertensive crisis | 10 (10) | 2 (2) |
| Heart failure | 9 (9) | 7 (7) |
| Gastrointestinal toxicity | 52 (50) | 4 (4) |
| Nausea | 37 (36) | 0 |
| Vomiting | 13 (13) | 1 (1) |
| Diarrhea | 7 (7) | 0 |
| Mucositis | 23 (22) | 3 (3) |
| Rash | 26 (25) | 2 (2) |
| Alopecia | 11 (11) | 0 |
Values represent n (%) of patients.